Manufacturer: ALP Laboratories
Pharmaceutical name: Human Chorionic Gonadotropin
Pack: 1 vial (5000iu)
HCG is a hormone that the female placenta generates naturally during a typical pregnancy. The functioning of this medication closely resembles that of luteinizing hormone (LH), which is recognized for its role in triggering ovulation. When used alongside other medications and treatments, HCG proves to be highly effective in aiding female patients in achieving pregnancy. This medication can also assist male patients facing fertility challenges, as it often leads to elevated testosterone production in such cases.
HCG is commonly prescribed to female patients as part of a treatment plan aimed at promoting: Ovulation induction in cases of subfertility usually caused by issues with follicle maturation or anovulation. - Luteal phase support. Preparation of follicles for retrieval in controlled ovarian hyperstimulation programs, typically associated with assisted reproductive techniques.
HCG is frequently prescribed for male patients due to its capacity to address hypogonadotropic hypogonadism. Some individuals suffering from idiopathic dysspermias have shown positive responses to treatment with this medication. It is also used for delayed puberty linked to inadequate function of the gonadotropic pituitary glands and for cryptorchidism, excluding cases resulting from abnormal anatomical obstructions.
HCG is a well-known treatment for infertility in both male and female patients. Additionally, this medication can be employed for various other medical purposes that are not detailed here.
For female patients seeking HCG treatment: Infertile women undergoing medically assisted reproduction, especially those requiring in vitro fertilization, often experience tubal abnormalities, which may lead to a higher incidence of ectopic pregnancies following HCG treatment. Consequently, early ultrasound confirmation at the onset of pregnancy (to determine whether the pregnancy is intrauterine) is essential. Pregnancies conceived after HCG treatment are at an increased risk of multiples. Female patients with a history of thrombosis, severe obesity, or thrombophilia should not receive this medication, as they face an elevated risk of arterial or venous thromboembolic complications during or after HCG treatment. Furthermore, women who have been treated with this medication are generally at a greater risk of experiencing pregnancy losses.